{"nctId":"NCT00502840","briefTitle":"A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.","startDateStruct":{"date":"2007-07-23","type":"ACTUAL"},"conditions":["Rheumatoid Arthritis"],"count":193,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: rituximab [MabThera/Rituxan]"]}],"interventions":[{"name":"rituximab [MabThera/Rituxan]","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adult patients with rheumatoid arthritis who participated in ML19070, and have completed the week 24 visit;\n* eligible for re-treatment (DAS28 \\>2.6 after week 24, swollen joint count \\>=4, tender joint count \\>=4).\n\nExclusion Criteria:\n\n* patients who have withdrawn from treatment in ML19070 pre-week 16;\n* patients with a previous response in DAS28 \\<0.6 to MabThera after week 16;\n* concurrent treatment with any DMARD except for methotrexate, any TNF alpha inhibitor, or other biologic or investigational agent.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in DAS28 Score at Week 24","description":"DAS28 calculated from the swollen joint count (SJC) and tender joint count (PJC) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour \\[mm/hour\\]) and Patient Global Asessment of disease activity (participant- rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). A clinically meaningful improvement in DAS28 was defined as an improvement of 1.2 units.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.12","spread":"1.41"}]}]}]},{"type":"SECONDARY","title":"DAS28 Score by Treatment Course and Follow-up (FU) Visit","description":"DAS28 was assessed during follow-up at the specified timepoints following each course of treatment (participants could have received up to 3 courses of treatment with rituximab). The DAS28 consists of SJC and TJC measurements, the ESR (measured in mm/hr), and Patient Global Asessment of disease activity (participant-rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. DAS28 less than or equal to (≤)3.2 equals (=) low disease activity, DAS28 \\>3.2 to 5.1 = moderate to high disease activity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.15","spread":"1.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.09","spread":"1.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.72","spread":"1.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.78","spread":"1.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.94","spread":"1.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.79","spread":"1.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.69","spread":"1.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.34","spread":"1.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.56","spread":"1.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.53","spread":"1.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.98","spread":"1.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.59","spread":"1.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.25","spread":"1.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.65","spread":"1.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.94","spread":"1.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.12","spread":"1.22"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With European League Against Rheumatism (EULAR) Response of 'Good' or 'Moderate' by Treatment Course","description":"DAS28 was assessed during follow-up at the specified timepoints following each course of treatment (participants could have received up to 3 courses of treatment with rituximab). The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders had a change from baseline \\>1.2 with a DAS28 score ≤3.2; moderate responders had a change from baseline \\>1.2 with a DAS28 score \\>3.2 to ≤5.1 or a change from baseline \\>0.6 to ≤1.2 with a DAS28 score ≤5.1.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Response By EULAR Category and Treatment Course","description":"Response was assessed during follow-up at the specified timepoints following each course of treatment (participants could have received up to 3 courses of treatment with rituximab). The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders had a change from baseline \\>1.2 with a DAS28 score ≤3.2; moderate responders had a change from baseline \\>1.2 with a DAS28 score \\>3.2 to ≤5.1 or a change from baseline \\>0.6 to ≤1.2 with a DAS28 score ≤5.1; non-responders had a change from baseline ≤0.6 or change from baseline \\>0.6 and ≤1.2 with a DAS28 score \\> 5.1.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Health Assessment Questionnaire - Disability Index (HAQ-DI) Score by Treatment Course","description":"HAQ-DI was assessed during follow-up at the specified timepoints following each course of treatment (participants could have received up to 3 courses of treatment with rituximab). The HAQ-DI score consists of questions referring to 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. For each of the categories, participants reported the amount of difficulty they had in performing 2 or 3 specific sub-category items. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. The standard disability score was calculated from the 8 categories by dividing the sum of the individual categories by the number of categories answered ;total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. The questionnaire was provided in a German translation and was scored based on the instructions from the Stanford University Medical Center.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.43","spread":"0.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.36","spread":"0.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.31","spread":"0.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.28","spread":"0.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.33","spread":"0.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.29","spread":"0.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.31","spread":"0.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.26","spread":"0.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.22","spread":"0.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.34","spread":"0.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.38","spread":"0.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":"0.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":"0.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":"0.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.12","spread":"0.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.35","spread":"0.57"}]}]}]},{"type":"SECONDARY","title":"Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score by Treatment Course","description":"FACIT-F was assessed during follow-up at the specified timepoints following each course of treatment (participants could have received up to 3 courses of treatment with rituximab). The FACIT fatigue scale is based on a 13-item questionnaire to assess the therapy-induced fatigue. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant's response to the questions (with the exception of 2 negatively stated), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (best) to 52 (worst). The assessment was originally developed for chronic illnesses and is now validated for patients with rheumatoid arthritis (RA). The questionnaire was provided in a German translation.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.16","spread":"11.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.48","spread":"11.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.81","spread":"12.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.75","spread":"11.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.17","spread":"12.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.77","spread":"13.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.43","spread":"11.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.19","spread":"11.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.77","spread":"11.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.86","spread":"11.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.40","spread":"10.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.71","spread":"11.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.82","spread":"12.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.98","spread":"11.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.70","spread":"12.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.40","spread":"12.74"}]}]}]},{"type":"SECONDARY","title":"Short-Form 36 (SF-36) Physical Composite Scores (PCS) by Treatment Course","description":"SF-36 was assessed during follow-up at the specified timepoints following each course of treatment (participants could have received up to 3 courses of treatment with rituximab). The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and mental composite t-score (MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.57","spread":"7.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.28","spread":"8.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.23","spread":"8.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.94","spread":"8.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.28","spread":"9.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.92","spread":"9.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.27","spread":"8.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.34","spread":"8.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.17","spread":"8.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.68","spread":"7.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.34","spread":"8.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.95","spread":"8.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.43","spread":"8.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.62","spread":"8.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.99","spread":"6.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.95","spread":"6.32"}]}]}]},{"type":"SECONDARY","title":"SF-36 MCS by Treatment Course","description":"SF-36 was assessed during follow-up at the specified timepoints following each course of treatment (participants could have received up to 3 courses of treatment with rituximab). The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and MCS. The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.04","spread":"12.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.32","spread":"12.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.06","spread":"12.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.18","spread":"12.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.35","spread":"13.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.95","spread":"14.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.94","spread":"11.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.99","spread":"11.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.29","spread":"11.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.93","spread":"13.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.90","spread":"12.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.22","spread":"10.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.52","spread":"13.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.38","spread":"12.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.41","spread":"13.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.67","spread":"13.73"}]}]}]},{"type":"SECONDARY","title":"SF-36 Domain Scores by Treatment Course - Physical Functioning","description":"SF-36 was assessed during follow-up at the specified timepoints following each course of treatment (participants could have received up to 3 courses of treatment with rituximab). The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and MCS. The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.26","spread":"24.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.80","spread":"25.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.85","spread":"25.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.58","spread":"26.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.30","spread":"26.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.92","spread":"30.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.17","spread":"24.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.03","spread":"24.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.10","spread":"24.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.50","spread":"22.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.41","spread":"23.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.01","spread":"26.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.35","spread":"26.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.32","spread":"28.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.23","spread":"26.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.99","spread":"29.37"}]}]}]},{"type":"SECONDARY","title":"SF-36 Domain Scores by Treatment Course - Bodily Pain","description":"SF-36 was assessed during follow-up at the specified timepoints following each course of treatment (participants could have received up to 3 courses of treatment with rituximab). The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and MCS. The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.22","spread":"18.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.06","spread":"20.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.98","spread":"22.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.70","spread":"21.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.55","spread":"25.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.10","spread":"25.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.15","spread":"20.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.34","spread":"21.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.38","spread":"22.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.23","spread":"20.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.58","spread":"24.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.60","spread":"18.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.94","spread":"18.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.92","spread":"21.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.24","spread":"19.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.56","spread":"18.49"}]}]}]},{"type":"SECONDARY","title":"SF-36 Domain Scores by Treatment Course - Physical Role Functioning","description":"SF-36 was assessed during follow-up at the specified timepoints following each course of treatment (participants could have received up to 3 courses of treatment with rituximab). The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the physical and mental composite t-scores (PCS and MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.85","spread":"23.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.04","spread":"24.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.28","spread":"24.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.92","spread":"24.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.51","spread":"25.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.44","spread":"25.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.79","spread":"24.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.54","spread":"21.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.32","spread":"23.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.91","spread":"20.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.98","spread":"20.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.32","spread":"21.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.47","spread":"25.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.99","spread":"23.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.82","spread":"23.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.49","spread":"22.84"}]}]}]},{"type":"SECONDARY","title":"SF-36 Domain Scores by Treatment Course - Emotional Role Functioning","description":"SF-36was assessed during follow-up at the specified timepoints following each course of treatment (participants could have received up to 3 courses of treatment with rituximab). The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the physical and mental composite t-scores (PCS and MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.80","spread":"27.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.91","spread":"26.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.44","spread":"28.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.12","spread":"26.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.52","spread":"28.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.98","spread":"30.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.30","spread":"25.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.74","spread":"25.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.53","spread":"25.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.75","spread":"26.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.05","spread":"23.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.29","spread":"25.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.26","spread":"29.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.53","spread":"26.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.51","spread":"31.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.39","spread":"25.84"}]}]}]},{"type":"SECONDARY","title":"SF-36 Domain Scores by Treatment Course - Emotional Well-Being","description":"SF-36 was assessed during follow-up at the specified timepoints following each course of treatment (participants could have received up to 3 courses of treatment with rituximab). The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and MCS. The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.71","spread":"21.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.38","spread":"20.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.70","spread":"20.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.26","spread":"20.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.08","spread":"23.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.85","spread":"24.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.44","spread":"19.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.33","spread":"19.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.45","spread":"19.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.67","spread":"20.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.82","spread":"19.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.43","spread":"18.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.99","spread":"24.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.46","spread":"20.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.80","spread":"20.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.88","spread":"21.20"}]}]}]},{"type":"SECONDARY","title":"SF-36 Domain Scores by Treatment Course - Social Functioning","description":"SF-36 was assessed during follow-up at the specified timepoints following each course of treatment (participants could have received up to 3 courses of treatment with rituximab). The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and MCS. The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.47","spread":"25.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.01","spread":"26.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.75","spread":"25.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.62","spread":"26.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.50","spread":"27.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.67","spread":"30.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.27","spread":"24.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.70","spread":"24.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.31","spread":"25.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.62","spread":"27.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.68","spread":"24.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.00","spread":"23.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.22","spread":"25.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.09","spread":"24.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.50","spread":"24.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.18","spread":"32.71"}]}]}]},{"type":"SECONDARY","title":"SF-36 Domain Scores by Treatment Course - Vitality","description":"SF-36 was assessed during follow-up at the specified timepoints following each course of treatment (participants could have received up to 3 courses of treatment with rituximab). The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and MCS. The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.33","spread":"20.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.51","spread":"21.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.22","spread":"20.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.57","spread":"21.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.82","spread":"22.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.99","spread":"22.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.60","spread":"20.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.42","spread":"20.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.01","spread":"21.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.49","spread":"19.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.30","spread":"18.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.93","spread":"24.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.35","spread":"24.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.14","spread":"24.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.25","spread":"26.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.97","spread":"23.92"}]}]}]},{"type":"SECONDARY","title":"SF-36 Domain Scores by Treatment Course - General Heath Perceptions","description":"SF-36 was assessed during follow-up at the specified timepoints following each course of treatment (participants could have received up to 3 courses of treatment with rituximab). The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and MCS. The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.74","spread":"15.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.46","spread":"16.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.82","spread":"16.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.65","spread":"16.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.38","spread":"18.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.15","spread":"17.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.32","spread":"14.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.04","spread":"14.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.93","spread":"14.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.04","spread":"16.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.98","spread":"18.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.27","spread":"13.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.14","spread":"14.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.90","spread":"12.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.54","spread":"12.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.29","spread":"14.37"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Percent (%), 50%, or 70% Improvement (ACR20/ACR50/ACR70) by Treatment Course","description":"ACR response was assessed during follow-up at the specified timepoints following each course of treatment (participants could have received up to 3 courses of treatment with rituximab). ACR20/50/70 response: ≥20/50/70%, respectively, improvement in SJC or TJC and 20/50/70% improvement in 3 of the following 5 criteria: 1) Physician's Global Assessment of Disease Activity, 2) Patient's Global Assessment of Disease Activity, 3) Patient's Assessment of Pain, 4) participants assessment of functional disability via HAQ-DI, and 5) C-reactive protein (CRP) or ESR at each visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Swollen Joint Count","description":"Mean sum of 28 swollen joints was assessed during follow-up at the specified timepoints following each course of treatment (participants could have received up to 3 courses of treatment with rituximab). The 28 joints to be assessed for swelling were shoulder, elbow, wrist, metacarpophalangeal (MCP) joints 1-5, proximal interphalangeal (PIP) joints 1-5, and knee on both sides of the body. The sum of swollen joints ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.52","spread":"5.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.09","spread":"5.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.65","spread":"4.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.51","spread":"5.01"}]}]}]},{"type":"SECONDARY","title":"Tender Joint Count","description":"Mean sum of 28 tender joints was assessed during follow-up at the specified timepoints following each course of treatment (participants could have received up to 3 courses of treatment with rituximab). The 28 joints to be assessed for tenderness were shoulder, elbow, wrist, MCP joints 1-5, PIP joints 1-5, and knee on both sides of the body. The sum of tender joints ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.92","spread":"9.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.32","spread":"9.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.31","spread":"7.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.00","spread":"9.02"}]}]}]},{"type":"SECONDARY","title":"Physician's Global Assessment of Disease Activity","description":"Physician's Global Assessment of Disease Activity was assessed during follow-up at the specified timepoints following each course of treatment (participants could have received up to 3 courses of treatment with rituximab). Baseline was defined as the original baseline score from assessment performed in Study ML19070. Physicians were to assess the disease activity on a 100-mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as \"no disease activity\" (symptom-free and no arthritis symptoms) and the right hand extreme (100 mm) as \"maximum disease activity\" (maximum arthritis disease activity).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.17","spread":"15.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.50","spread":"22.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.67","spread":"24.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.82","spread":"22.52"}]}]}]},{"type":"SECONDARY","title":"Patient's Global Assessment of Disease Activity","description":"Patient Global Assessment of Disease Activity was assessed during follow-up at the specified timepoints following each course of treatment (participants could have received up to 3 courses of treatment with rituximab). Baseline was defined as the original baseline score from assessment performed in Study ML19070. Participants were to assess the disease activity on a 100-mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as \"no disease activity\" (symptom-free and no arthritis symptoms) and the right hand extreme (100 mm) as \"maximum disease activity\" (maximum arthritis disease activity).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.40","spread":"21.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.13","spread":"23.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.50","spread":"23.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.66","spread":"23.77"}]}]}]},{"type":"SECONDARY","title":"Patient's Assessment of Pain","description":"Patient Assessment of Pain was assessed during follow-up at the specified timepoints following each course of treatment (participants could have received up to 3 courses of treatment with rituximab). Baseline was defined as the original baseline score from assessment performed in Study ML19070. Participants were to assess their current level of pain on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as \"no pain\" and the right-hand (100 mm) as \"unbearable pain\".","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.90","spread":"21.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.02","spread":"23.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.12","spread":"23.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.82","spread":"25.63"}]}]}]},{"type":"SECONDARY","title":"C-Reactive Protein","description":"CRP measured in milligrams per deciliter (mg/dL) was assessed during follow-up at the specified timepoints following each course of treatment (participants could have received up to 3 courses of treatment with rituximab). Baseline was defined as the original baseline score from assessment performed in Study ML19070.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.82","spread":"2.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":"1.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.88","spread":"1.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.84","spread":"0.96"}]}]}]},{"type":"SECONDARY","title":"Erythrocyte Sedimentation Rate","description":"ESR mean scores measured in mm/hr at was assessed during follow-up at the specified timepoints following each course of treatment (participants could have received up to 3 courses of treatment with rituximab). Baseline was defined as the original baseline score from assessment performed in Study ML19070.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.30","spread":"19.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.87","spread":"14.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.45","spread":"16.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.74","spread":"11.59"}]}]}]},{"type":"SECONDARY","title":"Rheumatoid Factor (RF)","description":"RF measured in international units per milliliter (IU/mL) was assessed during follow-up at the specified timepoints following each course of treatment (participants could have received up to 3 courses of treatment with rituximab). Baseline was defined as the original baseline score from assessment performed in Study ML19070.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"187.18","spread":"339.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.16","spread":"163.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.17","spread":"144.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.52","spread":"117.73"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":47,"n":193},"commonTop":["Nasopharyngitis","Bronchitis","Upper respiratory tract infection","Diarrhoea","Gastroenteritis"]}}}